Published: Circulation, 2026 (Published February 24, 2026) Societies: ACC, AHA, HRS, ISACHD, SCAI DOI: 10.1161/CIR.0000000000001402 Guideline Type: Full Revision of 2018 ACHD Guideline with Comprehensive Updates
Adult Congenital Heart Disease (ACHD) Overview
Key Facts About ACHD:
ACHD population now exceeds pediatric congenital heart disease population in developed countries with estimated 1.5-2 million adults in the U.S.
Requires lifelong specialized care at dedicated ACHD centers with multidisciplinary teams including cardiology, cardiac surgery, electrophysiology, and maternal-fetal medicine
Anatomic and Physiologic (AP) Classification System guides all management decisions regarding surveillance intensity, testing frequency, and intervention timing
Structured transition programs critical to prevent loss to follow-up during adolescence-to-adulthood transfer; gap in care increases morbidity/mortality
Major barriers to care: geographic disparity in specialist availability, insufficient numbers of ACHD specialists, insurance limitations, and inadequate transition infrastructure
Outcomes significantly better at specialized ACHD centers vs. general cardiology practices; evidence supports regionalization of care
ACHD Program Infrastructure & Personnel
Recommended Program Components
ACHD board-certified cardiologists with advanced training and ongoing expertise in congenital physiology
Congenital cardiac surgeons experienced in surgical repair/revision in adult ACHD populations
Progressive cyanosis, polycythemia, thrombosis, arrhythmias, sudden death
Clinical Pearl: The "hidden epidemic" of undiagnosed ACHD exists; many adults with simple lesions (especially ASD) were never repaired or followed. Systematic screening during transitions to adult care identifies previously undiagnosed lesions.
ACHD Anatomic & Physiologic (AP) Classification System
Purpose & Application: The AP Classification stratifies disease complexity and severity to:
Guide intensity of diagnostic testing and surveillance frequency
Determine clinical follow-up intervals and specialist involvement
Inform timing of interventions, procedures, and surgical repair/revision
Risk-stratify patients for complications, adverse events, and need for device therapy
Standardize communication between providers and coordinate care across institutions
Anatomic Complexity Categories
Level
Characteristics
Examples
Simple
Single lesion with low surgical complexity; excellent prognosis
Isolated ASD (secundum), small PDA, small restrictive VSD, mild PS, mitral stenosis
Moderate
Lesion with moderate surgical complexity or residual defects; multifactorial physiology
ASD with PAH, moderate VSD, repaired Tetralogy of Fallot, Ebstein anomaly, unrepaired coarctation
Complex
Multiple defects or single ventricle physiology; highest surgical/medical complexity
Double-outlet RV, Fontan physiology, CCTGA, truncus arteriosus, transposition, PA atresia with major aortopulmonary collaterals
Physiologic Stage Assessment (A-D)
Stage
Clinical Characteristics
Biomarkers/Findings
A
No cardiac symptoms, normal/excellent exercise capacity, no sustained arrhythmias
Normal NT-proBNP, no LV dilation, normal LVEF ≥60%
B
Mild/no arrhythmias, mild valve disease, no or mild functional limitation with exercise
Normal-mildly elevated NT-proBNP (<2× ULN), no sustained arrhythmias
C
BNP/NT-proBNP ≥2× ULN OR sustained arrhythmias requiring treatment OR prior cardiac event
HF hospitalization within past 12 months, endocarditis, NYHA II-IV symptoms, cyanosis
Severe LV/RV dysfunction, reduced EF <40%, worsening renal/hepatic function
Critical Concept: Overall ACHD class determined by the maximum of anatomic complexity and physiologic stage. A patient with "Simple-D" ACHD (e.g., ASD with acute HF) receives care intensity appropriate for "D" stage. More complex anatomy and advanced physiologic stages warrant more intensive surveillance, earlier diagnostic intervention, and aggressive medical management.
AP Classification Application Examples
Clinical Scenario
AP Class
Management Intensity
Asymptomatic secundum ASD, normal RV, Qp:Qs <1.5
Simple-A
Low: follow-up q3-5 years; echo q3-5 years
Secundum ASD with RV dilation, Qp:Qs 1.5-1.8, mild dyspnea
Simple-B or Moderate-B
Moderate: q1-2 year clinic visits; echo annually; closure indicated
Repaired ToF, LVEF 50%, QRS 160ms, no arrhythmias
Moderate-B
Moderate: q1-2 year visits; EP evaluation recommended
Repaired ToF, LVEF 35%, QRS 200ms, prior NSVT on monitor
Moderate-D
Intensive: q3-6 month visits; ICD evaluation urgent; admission for monitoring
COR 1, LOE B-NR: All ACHD patients should receive structured, patient-centered, developmentally appropriate transition education beginning in early adolescence (ages 12-14 years). Education must cover: specific diagnosis, underlying anatomy and physiology, previous surgical procedures and repairs, anticipated complications/risks, medications, and critical importance of lifelong cardiology follow-up.
COR 1, LOE B-NR: Congenital heart disease programs and pediatric cardiologists should establish institutional policies and procedures ensuring effective handoffs to adult ACHD providers. Utilize dedicated transition coordinators, nurse navigators, and social workers to facilitate successful care transitions and maintain continuity.
COR 2a, LOE B-NR: Transition education should result in seamless transfer from pediatric to ACHD providers with concurrent involvement of both teams for 12-24 months overlapping period. Detailed transition summaries with surgical records, imaging, and past catheterization data essential.
Transition Outcomes: Transition outcomes worsen significantly with age at transfer; optimal timing is between ages 16-18 years with graduated transfer timeline over 1-3 years. Annual assessment of transition readiness and care management skills (medication adherence, appointment keeping, shared decision-making) is essential. Loss to follow-up during transition period correlates with worse long-term outcomes including increased hospitalizations and mortality.
COR 1, LOE B-R: Antibiotic prophylaxis is recommended for high-risk lesions: unrepaired cyanotic lesions (including complex palliative procedures like Blalock-Taussig shunt), lesions with residual defects after surgical or percutaneous repair (within 6 months post-procedure), and patients with previous history of infective endocarditis.
COR 2a, LOE B-NR: Prophylaxis may be considered for moderate-risk lesions: secundum ASD (except uncomplicated cases), repaired VSD without residual defect ≥6 months post-procedure, and mild pulmonary stenosis.
COR 3, LOE B-NR: Prophylaxis is not recommended for isolated secundum ASD without other defects or for completely repaired simple lesions ≥6 months without residual defects.
Prophylaxis Regimen
Route & Dosing
Timing Relative to Procedure
Amoxicillin (standard, oral)
2 g PO
30-60 min pre-procedure
Cephalexin (oral)
2 g PO
30-60 min pre-procedure
Azithromycin (PCN-allergic, oral)
500 mg PO
30-60 min pre-procedure
Ceftriaxone IV (high-risk/unable to take oral)
1 g IV/IM
Immediately pre-procedure
Clindamycin (allergy/resistance, oral or IV)
600 mg PO/IV
30-60 min pre-procedure
Vancomycin IV (complicated PCN allergy)
15-20 mg/kg IV
Complete infusion pre-procedure
Common Endocarditis Prophylaxis Pitfalls
Prophylaxis administration >2 hours before procedure or delayed significantly reduces effectiveness
Failure to cover dental work (scaling, extraction, periodontal surgery), GI procedures (EGD, colonoscopy with polyp removal), and GYN procedures (hysterectomy, dilation and curettage)
Assuming 6-month cure period universal for all defects; varies significantly by defect type and repair technique (transannular patch higher risk)
Inadequate penicillin dosing or failure to adjust for body weight and renal function in adults
Using prophylaxis as substitute for dental hygiene and infection control; emphasize good oral hygiene and regular dental care
Diagnostic Imaging Strategy & Modality Selection
Selection of imaging modality depends on ACHD anatomic complexity, specific clinical question, radiation exposure, and absolute/relative contraindications:
Gold standard hemodynamic assessment; enables interventional therapy
Invasive; requires expertise; not benign (stroke risk ~0.5%, MI ~0.1%, death ~0.1%)
Imaging Algorithm: Start with TTE as baseline. Advanced imaging (MRI or CT) indicated for: complex anatomy assessment, need for volumetric measurement, coronary anomaly evaluation, or inadequate echo window. Reserve catheterization for hemodynamic assessment or intervention.
COR 1, LOE B-R: ASD closure is recommended in patients with evidence of RV volume overload (Qp:Qs ratio ≥1.5:1) regardless of symptoms, and in asymptomatic patients with imaging evidence of RV dilation (RV end-diastolic area >23 cm²/m²).
COR 2a, LOE B-NR: Closure may be considered in asymptomatic patients with Qp:Qs 1.3-1.5:1 and documentation of RV dilation on serial imaging studies over time (serial TTE showing progressive changes).
COR 3, LOE B-R: Closure is not recommended in patients with pulmonary arterial hypertension with elevated Rp/Rs ratio ≥1.0 without hemodynamic evidence of net left-to-right shunting (contraindication due to acute RV failure risk post-closure).
ASD Follow-up Strategy by AP Class
AP Class
Clinical Follow-up
Imaging (TTE)
Advanced Imaging (MRI/CT)
Intervention Threshold
Simple-A
Every 3-5 years
Every 3-5 years
As clinically indicated for questionable anatomy
If Qp:Qs ≥1.5:1 OR RV area significantly enlarged on echo
Simple-B
Every 1-2 years
Annually
Every 2-3 years if progressive changes
Earlier closure consideration with mild LV dysfunction
Moderate-C/D
Every 3-6 months
Every 6-12 months
Every 1-2 years to assess trajectory
Urgent closure if hemodynamic deterioration, HF symptoms, significant arrhythmia burden
Serial Assessment Key: RV area and TAPSE/PASP ratio on echocardiography predict RV dysfunction trajectory better than single shunt quantitation. Serial measurement of RV function at 1-2 year intervals is critical for optimal closure timing; progressive RV dilatation on repeat imaging warrants earlier closure consideration even if Qp:Qs borderline.
Ventricular Septal Defect (VSD) Management in Adults
VSD Closure Indications
COR 1, LOE B-R: Closure is recommended in patients with hemodynamically significant VSD (Qp:Qs ≥1.5:1 or imaging evidence of LV volume overload) and normal or low-normal pulmonary artery pressures (Rp/Rs <0.3, mPAP <35 mmHg).
COR 2a, LOE C-LD: Closure may be considered in asymptomatic patients with Qp:Qs 1.3-1.5:1 if progressive LV dilation or declining LV systolic dysfunction documented on serial imaging over 1-2 years.
COR 3, LOE B-R: Closure not recommended in restrictive VSDs without hemodynamic evidence of shunting or progressive LV dysfunction. Observation with serial imaging appropriate for small restrictive defects.
Patent Ductus Arteriosus (PDA) in Adults
PDA Closure Indications
COR 1, LOE B-R: PDA closure is recommended in patients with hemodynamically significant shunt (Qp:Qs ≥1.5:1) or imaging evidence of LV dilation or systolic dysfunction attributable to the PDA. Transcatheter closure preferred if anatomy suitable.
COR 2a, LOE C-LD: Closure may be considered in small-to-moderate shunts with borderline hemodynamic changes on serial imaging and preserved LV function to prevent late deterioration.
PDA Closure Device Selection
Percutaneous transcatheter closure: Preferred for most patients; device options include Amplatzer Duct Occluder (ADO, ADO II, ADO II Additional Sizes), Coil embolization, and newer repositionable devices
Surgical ligation/division: Reserved for large/complex anatomy unsuitable for percutaneous approach, extremely small body size, or failed percutaneous attempts
Medical closure (NSAIDs/Indomethacin/Ibuprofen): Not recommended in adults; indomethacin/ibuprofen effective only in preterm infants, ineffective in older patients
PDA Pitfall: Do not assume "small PDA" is benign in adults; even modest left-to-right shunting can lead to progressive LV dilation over years. Serial echo assessment every 2-3 years appropriate to detect progressive chamber dilation warranting intervention.
COR 1, LOE C-LD: All adults with bicuspid aortic valve require comprehensive baseline cardiac imaging to assess: aortic root diameter at sinuses of Valsalva and ascending aorta, severity of aortic stenosis and aortic regurgitation, left ventricular systolic function (LVEF), and presence of associated lesions. Baseline echocardiography and/or cardiac CT/MRI essential.
COR 2a, LOE B-NR: Surveillance imaging intervals should be individualized based on: baseline aortic root diameter, degree of valve dysfunction, family history of aortic dissection/sudden death, presence of concomitant hypertension, and planned pregnancy. More aggressive surveillance in intermediate-risk features.
BAV Dissection Risk: Aortic root dissection risk is markedly elevated with aortic root diameter >5.0-5.5 cm, particularly in setting of concurrent hypertension, pregnancy, or connective tissue disease. Do not rely on echo-derived measurements alone; cardiac CT or MRI recommended for definitive diameter measurement, especially when planning pregnancy or major life events. Consider elective aortic root replacement at >5.5 cm or at lower thresholds if family history of dissection/sudden death or pregnancy planned.
Coarctation of Aorta (CoA) Management & Complications
Coarctation Intervention Indications
COR 1, LOE C-LD: Intervention (surgical repair, endovascular stent, or percutaneous balloon angioplasty) is recommended in patients with peak systolic pressure gradient ≥20 mmHg at rest across coarctation site OR persistent hypertension despite optimal medical management (2+ antihypertensive agents).
COR 2a, LOE C-LD: Intervention may be considered in patients with gradient 10-20 mmHg if any of the following: progressive aortic dilation, LV hypertrophy with dysfunction, end-organ dysfunction (chronic kidney disease, stroke history, LV dysfunction).
Complication of CoA
Screening/Monitoring Strategy
Intervention Threshold/Treatment
Hypertension
Home BP monitoring; 24-hour ambulatory BP regularly; office checks
SBP ≥140/90 on ≥2 agents warrants re-intervention assessment; restart ACE-I/ARB if off
Aortic root enlargement
Cardiac imaging (echo or MRI) every 1-2 years after intervention; every 2-3 years if stable
Aortic root >5.0-5.5 cm warrants surgical consideration; monitor for dissection risk
Restenosis
Serial peak systolic gradients on echo/MRI; annual Doppler in first 5 years post-intervention
Gradient >20 mmHg with clinical symptoms warrants re-intervention (PTA/stent vs surgery)
Renal artery stenosis
Renal Doppler or CT/MRI angiography yearly if history of intervention; creatinine/eGFR
If renal artery stenosis >70% with resistant hypertension, consider revascularization
Aortic rupture (rare)
Imaging for progressive dilation; counsel on Valsalva avoidance, heavy lifting
Emergency repair if rupture occurs; prevent with elective repair of severely dilated aorta
CoA Recoarctation Risk: Recoarctation occurs in approximately 25-30% of balloon-dilated CoA but only 5-10% of surgically repaired CoA. Long-term imaging follow-up (echo/MRI annually for 5 years, then every 2-3 years) essential for all intervention types. Endovascular stent grafting shows promise for reducing recoarctation but long-term outcomes still being evaluated.
Observation; no intervention; follow-up every 3-5 years
Moderate
36-80
0.6-1.0
Usually normal; monitor RV size
Observation if asymptomatic; PVR if gradient >60-70 mmHg with symptoms or RV changes
Severe
>80
<0.6
Often dilated; dysfunction
PVR indicated; strongly consider intervention even if asymptomatic if RV dysfunction, dilation
Pulmonary Valve Replacement Indications
COR 1, LOE B-NR: PVR is recommended in severe pulmonary stenosis (peak gradient >80 mmHg) with RV dilatation/systolic or diastolic dysfunction, or progressive RV dysfunction on serial imaging.
COR 2a, LOE C-LD: PVR may be considered in moderate pulmonary stenosis (gradient 60-80 mmHg) with evidence of RV systolic or diastolic dysfunction, progressive cardiac chamber enlargement, exercise limitation, or asymptomatic severe stenosis with declining RV function on follow-up.
Pathophysiology Overview: Ebstein anomaly involves apical displacement of the septal leaflet and posterior leaflet of the tricuspid valve, effectively "atrialization" of the RV. Wide clinical spectrum from asymptomatic with excellent prognosis to severe heart failure with cyanosis and arrhythmias. Associated lesions include ASD (~80%), PFO, and accessory pathways (Wolff-Parkinson-White syndrome in ~25%).
Echocardiographic Severity Grading
Mild Ebstein: Septal leaflet apical displacement <0.5 cm/m² BSA, RV and RA dimensions not significantly increased, minimal TR, normal RV function
Surgical repair/valvuloplasty vs replacement indicated; transplant evaluation if not surgical candidate
Ebstein Anomaly Management Pitfalls
Underestimating progressive RV/RA enlargement on serial imaging; annual TTE recommended to assess trajectory
Failing to diagnose associated accessory pathways; perform ECG screening at baseline; refer for EP evaluation if Delta wave present or SVT symptoms
Missing concomitant ASD/PFO (present in ~80%); comprehensive imaging essential to avoid cyanosis from right-to-left shunt
Inappropriate expectant management in symptomatic patients; modern surgical outcomes excellent; consider surgery earlier rather than late when RV severely dysfunctional
Not monitoring for paradoxical embolism risk if ASD/PFO; avoid dehydration; consider anticoagulation/antiplatelet therapy
Complex Lesions: Fontan, Tetralogy of Fallot, Transposition
Fontan Circulation Principles: Total cavopulmonary connection establishes direct passive flow from IVC/SVC to pulmonary arteries, bypassing the RV entirely. Functional single ventricle acts as systemic ventricle. Success depends on: lower PA pressures, preserved RV (systemic ventricle) function, normal pulmonary vascular resistance, and favorable ventricular mechanics. Complications develop progressively as Fontan circulation ages (typically after 15-20+ years post-Fontan).
Fontan Complication Surveillance Algorithm
COR 1, LOE B-NR: All Fontan patients require systematic surveillance for: systemic ventricular dysfunction (reduced LVEF or RVEF), atrial arrhythmias (both SVT and atrial fibrillation, often paroxysmal initially progressing to permanent AF), thromboembolic complications (especially with AF), plastic bronchitis with hemoptysis, hepatic cirrhosis/portal hypertension (Fontan-associated liver disease), and renal dysfunction.
COR 2a, LOE C-LD: Anticoagulation with warfarin (INR target 2.5-3.5) should be considered in Fontan patients with atrial arrhythmias, reduced ventricular function (LVEF/RVEF <40%), or elevated thrombotic risk (prior stroke/TIA, intracardiac thrombus on imaging).
Fontan Complication
Screening/Detection Method
Frequency
Management Strategy
Systemic Ventricular Dysfunction
Baseline and serial TTE (LVEF/RVEF measurement), periodic MRI volumetric assessment, troponin/BNP screening
Every 1-2 years; annually if reduced EF
GDMT (ACE-I/ARB, beta-blocker, aldosterone antagonist); SGLT2 inhibitor consideration; advanced therapies if EF <35%
Atrial Arrhythmias (SVT, AF)
Baseline 12-lead ECG, periodic 24-48hr Holter/event monitor if symptoms, EP study if sustained arrhythmia
Baseline, then annually or with symptoms
Rhythm control (Class IC flecainide, Class III amiodarone/sotalol) preferred; anticoagulation if AF; ablation for refractory cases
Thromboembolic Events
Brain MRI screening if AF, prior stroke/TIA, or intracardiac thrombus on imaging; transcranial Doppler if emboli risk
Baseline if high-risk features; repeat every 3-5 years
Anticoagulation (warfarin INR 2.5-3.5 or DOAC); aspirin monotherapy insufficient; superior vena cava filter rarely needed
Anatomic Components: Ventricular septal defect (VSD), RV outflow tract obstruction (pulmonary stenosis), RV hypertrophy, and aortic override. Surgical repair involves VSD patch closure and pulmonary stenosis relief (usually via transannular patch if PS severe).
Progressive Issues with Aging: Pulmonary regurgitation (nearly universal post-transannular patch repair), progressive RV dilation over decades, atrial and ventricular arrhythmias, sudden cardiac death risk (~2-3% lifetime risk), systemic LV dysfunction (less common but increasingly recognized), and need for pulmonary valve replacement.
Repaired ToF Sudden Cardiac Death Risk Stratification
COR 1, LOE B-NR: All repaired ToF patients age ≥16 years require baseline comprehensive SCD risk assessment including: 12-lead ECG (QRS duration measurement), cardiac imaging (RV size/function, LVEF, pulmonary regurgitation severity), exercise stress testing, 24-48hr Holter monitor (assess for NSVT), and consideration of invasive EP testing if high-risk features present.
COR 2a, LOE B-NR: ICD implantation should be considered for patients with multiple SCD risk factors: markedly prolonged QRS duration (>180 ms, especially if >200 ms), moderate-to-severe RV dysfunction (RVEF <35%), history of sustained ventricular arrhythmias, inducible VT on EP study, or combination of risk factors using validated scoring tools.
SCD Risk Factor
Abnormal Threshold/Definition
Relative Weight in Risk Calculation
QRS Duration
>180 ms (very high risk); 160-180 ms (high risk); >120 ms (abnormal)
Strong independent predictor; each 10 ms increase associated with increased risk; >200 ms highest risk
RV Systolic Dysfunction
RVEF <35%; RV dilation (RVEDV >150 mL/m²)
Strong association with SCD and arrhythmias; combination of RV dilation + QRS >180 ms = very high risk
LV Systolic Dysfunction
LVEF <40%; regional wall motion abnormalities
High-risk feature often overlooked; requires careful assessment on echo/MRI; indicates multi-ventricular involvement
Non-Sustained Ventricular Tachycardia
VT runs ≥3 beats on Holter monitoring <120 sec; single runs or multiple runs?
Significant risk stratifier; presence warrants EP study to assess for inducible sustained VT
Inducible Ventricular Tachycardia
Sustained VT induced with ≤2 extra beats at 2 sites; hemodynamically tolerated vs unstable VT
Direct ICD indication; hemodynamic instability increases risk significantly
Late Gadolinium Enhancement (MRI)
Presence of LGE in RV outflow tract, septal scar, or LV wall; extent/distribution
Emerging risk marker; greater extent associated with increased arrhythmia risk; research ongoing
Risk Scoring Tools: PREVENTION-ACHD score and FACES score validate ToF-specific SCD risk. Calculate these validated tools at baseline age ≥16 years for all repaired ToF patients to guide ICD decision-making and surveillance intensity. Serial assessment every 2-3 years recommended as some risk factors change over time.
Transposition of the Great Arteries (d-TGA) Post-Arterial Switch
Arterial Switch Operation (Jatene Procedure) Late Complications
Coronary Complications (Most Serious): Coronary artery ostial stenosis (risk ~2-5% over 20+ years; may present with sudden death or progressive angina), intimal proliferation, and rarely acute coronary syndrome even at young ages
Aortic Root Complications: Progressive aortic root dilation (occurs in ~20-50% of patients) and aortic insufficiency, potentially leading to need for aortic valve replacement/root replacement in adulthood
Left Ventricular Dysfunction: LV systolic dysfunction (historically thought to be related to subaortic stenosis from pulmonic stenosis bands, but actual incidence ~5-15% and etiology unclear; may be related to coronary issues or myocardial adaptation post-switch)
Arrhythmias & Sudden Death: Both SVT and VT can occur, particularly in setting of coronary stenosis or myocardial ischemia; sudden cardiac death risk ~1-2% over 20 years post-switch
COR 1, LOE B-NR: All arterial switch patients require systematic surveillance for coronary artery origin/stenosis, aortic root dimensions and progression, LV systolic and diastolic function, and exercise capacity/symptoms.
COR 2a, LOE B-NR: Cardiac CT or invasive angiography should be considered if: echocardiographic suspicion of coronary anomaly, progressive LV dysfunction on serial studies, exercise-induced symptoms (chest pain, syncope, severe dyspnea), ECG changes (ST depression), or routine screening based on institutional protocol.
d-TGA Comprehensive Surveillance Schedule
Baseline Assessment (Age 8-10 or at ACHD transfer): Detailed TTE assessing LV systolic/diastolic function, LVEF, aortic root size, aortic insufficiency, and any evidence of LV obstruction. 12-lead ECG baseline.
Periodic Transthoracic Echocardiography: Every 1-3 years if normal baseline; annually if aortic root dilation detected or LV dysfunction present. Measure aortic root dimensions at multiple levels and serially.
Cardiac Magnetic Resonance Imaging: Consider at ages 10-15 years for comprehensive coronary artery definition and aortic root 3D measurement if not previously performed; helps identify anomalous origins early
Cardiac Computed Tomography Angiography: Reserve for specific indications (concerns for coronary anomaly, unclear echo findings, or planning for intervention); provides excellent coronary definition and dimensions
Exercise Stress Testing: Consider at puberty/ages 13-15 to assess for exercise-induced ischemia, symptoms, or hemodynamic response abnormalities; repeat every 3-5 years in young adults
Invasive Coronary Angiography: Reserved for clinical suspicion of significant stenosis on non-invasive testing, therapeutic need for PTCA/stent for ostial stenosis, or evaluation of sudden cardiac death survivors
COR 1, LOE B-NR: All women with congenital heart disease of childbearing age and potential should receive structured, comprehensive preconception counseling including: maternal cardiovascular and obstetric risks, fetal risks, optimal timing of pregnancy if high-risk, need for multidisciplinary team involvement (obstetrics, anesthesia, cardiology), medication safety assessment, and contraception options.
COR 2a, LOE C-LD: Advanced imaging (cardiac MRI) and maximal exercise stress testing may be considered in moderate-to-high risk ACHD lesions prior to pregnancy to quantify risks accurately and guide peripartum management strategy.
Risk Category
Maternal Mortality Risk
Clinical Characteristics/Examples
Counseling Approach
Low Risk (<1%)
<1%
Repaired simple lesions (ASD, VSD, PDA), mild PS, mild AR/AS, normal LV function
Pregnancy generally safe; standard obstetric care; cardiology follow-up every trimester
Use cautiously; preferred if preeclampsia risk; avoid as monotherapy for HTN management
Hydrochlorothiazide or furosemide reasonable; monitor for maternal dehydration
Anticoagulation (Warfarin)
Teratogenic 1st trimester
Fetal warfarin syndrome; CNS abnormalities; bone dysplasia risk
LMWH preferable; vitamin K antagonists if mechanical valve (complex management with maternal-fetal medicine)
Pregnancy Planning in ACHD: Multidisciplinary pregnancy planning significantly reduces maternal-fetal morbidity/mortality. Essential team: maternal-fetal medicine specialist, cardiologist, cardiac surgeon (if surgery may be needed), obstetric anesthesiologist, and obstetric nurses. Preconception optimization of cardiac status, medication review, baseline testing, and delivery planning (vaginal vs. cesarean, epidural safety) improve outcomes substantially.
Exercise Prescription & Sports Participation in ACHD
Pre-Participation Cardiovascular Evaluation
Components of Pre-Participation Assessment
COR 1, LOE C-LD: All ACHD patients considering structured exercise or sports participation should undergo comprehensive cardiovascular risk assessment including: detailed symptom history (chest pain, syncope, severe dyspnea, palpitations with exertion), functional capacity history, resting and exercise electrocardiogram (ECG, stress testing if indicated), baseline cardiac imaging (TTE at minimum, MRI for complex lesions), and consideration of invasive testing (EP study) if arrhythmia risk.
COR 2a, LOE C-LD: Individualized exercise prescription recommended based on specific ACHD lesion type, hemodynamic parameters, arrhythmia risk profile, and measured functional capacity. Most ACHD patients benefit from regular moderate aerobic activity even with sport restrictions.
Exercise Recommendations by ACHD Category
ACHD Category
Expected Exercise Capacity
Recommended Activity Level
Sport Restrictions
Simple, asymptomatic (ASD, PDA repaired)
Unrestricted; normal VO₂ max
Unrestricted aerobic activity; no limitation
All sports permitted; participate as tolerated
Moderate, good functional capacity (repaired VSD)
70-85% age-predicted maximum HR capacity
Aerobic exercise to 70-80% max HR; avoid intense sustained competition
Restrict contact sports if on anticoagulation; limit high-intensity competitive sports
Complex, reduced LV function (LVEF 40-50%)
50-70% age-predicted capacity; limited by dyspnea/fatigue
Mild activity only; avoid dehydration and hypoxic stress challenges
Severely restrict all sports; avoid high altitude/hot climates; avoid Valsalva (sudden pressure increases cyanosis/syncope risk)
Systemic RV dysfunction (Fontan, s/p TGA switch)
Variable; 40-70% capacity depending on EF and arrhythmia
Moderate activity; avoid sustained intense exercise; tailored to tolerance
Restrict competitive sports if EF <35% or significant arrhythmia history; limit extreme exertion
Exercise Stress Testing Value: Maximal exercise stress testing guides safe intensity prescription better than anatomic diagnosis alone. Assessment of: blood pressure response to exercise (inadequate rise or paradoxical drop suggests high risk), exercise-induced arrhythmias (NSVT, SVT onset with exertion), and symptom reproduction (angina, severe dyspnea, presyncope) warrants more restrictive recommendations or further investigation.
Arrhythmia Management in ACHD
Supraventricular Tachycardia (SVT) Management
SVT Evaluation & Treatment Algorithm
COR 1, LOE B-NR: Patients with ACHD and documented or suspected SVT should be referred for comprehensive electrophysiology evaluation including: Holter monitoring to define mechanism and burden, exercise testing to assess inducibility, and EP study if recurrent/symptomatic episodes or treatment planning needed.
COR 2a, LOE C-LD: Radiofrequency or cryoablation is preferred for accessory pathway-mediated tachycardia (AVNRT, AVRT, orthodromic reciprocating tachycardia) in suitable anatomy. For atrial reentry tachycardia (common in repaired lesions), ablation considered if frequent symptomatic episodes or high burden despite first-line drug therapy.
Atrial Fibrillation in ACHD: Risk Stratification & Treatment
COR 1, LOE B-NR: Atrial fibrillation in ACHD is associated with significantly increased thromboembolic stroke risk. All ACHD patients with documented AF should be strongly considered for anticoagulation (warfarin target INR 2.5 or DOAC) unless very early paroxysmal AF in exceptionally low-risk patient with no additional risk factors.
COR 2a, LOE C-LD: Rhythm control strategy (antiarrhythmic drugs Class I or III agents, or ablation) generally preferred over rate control in most ACHD lesions to preserve AV synchrony, maintain atrial transport function, and prevent progressive atrial dilation/arrhythmia burden.
AF Anticoagulation Risk Assessment (CHA₂DS₂-VASc Score Modified for ACHD)
Low Risk (Score 0-1): Anticoagulation not routinely recommended; aspirin reasonable
Moderate Risk (Score 2): Anticoagulation reasonable if additional ACHD-specific risk factors or AF burden high
High Risk (Score ≥3): Anticoagulation strongly recommended regardless of AF paroxysmal vs. persistent
COR 2a, LOE B-NR: Non-sustained VT documented on ambulatory monitoring (Holter ≥3 beats lasting <120 sec) in ACHD warrants prompt EP evaluation including: baseline electrophysiology study to assess inducibility of sustained VT, risk stratification using clinical parameters (QRS duration, imaging findings), and discussion of ICD therapy if high-risk features present.
Sustained VT Management
COR 1, LOE B-NR: Sustained VT in ACHD is direct indication for ICD implantation and consideration of VT ablation if anatomy suitable and procedure expertise available. Acute hemodynamic instability requires synchronized cardioversion immediately.
Arrhythmia Type
Acute Hemodynamically Stable Management
Acute Unstable/Sustained Management
Chronic Management
SVT
Adenosine 6mg IV bolus, then 12mg if needed; vagal maneuvers
Synchronized cardioversion 50-100 J; sedation if conscious
Beta-blocker or CCB; Class IC antiarrhythmic (flecainide); ablation if recurrent
Atrial Flutter
Adenosine trial; if ineffective, rate control with beta-blocker/CCB
Synchronized cardioversion 100 J; sedation
Rate control (beta-blocker, CCB) or rhythm control (Class I/III); anticoagulation; ablation if recurrent
Atrial Fibrillation
IV rate control (beta-blocker, diltiazem); avoid adenosine
ICD if EF <35% or prior SCD event; amiodarone bridge; EP-guided catheter ablation; avoid QT-prolonging drugs
ACHD-Specific Arrhythmia Considerations: ACHD-related arrhythmias frequently refractory to single antiarrhythmic therapy; combination drugs and specialist EP consultation often essential. Structural complexity (especially in repaired lesions with extensive scarring) may preclude successful catheter ablation. Focus on medical optimization and ICD therapy when indicated. Avoid QT-prolonging drugs in susceptible patients.
Heart Failure & Cardiac Transplantation in ACHD
GDMT for ACHD Heart Failure with Reduced EF
Guideline-Directed Medical Therapy Algorithm
COR 1, LOE B-R: All ACHD patients with reduced LVEF or RVEF (<50%) should receive evidence-based GDMT: ACE-I (or ARB if ACE-I intolerant, or ARNI if available), beta-blockers (target doses), and aldosterone antagonists (target doses), titrated over weeks to months to goal doses as tolerated.
COR 2a, LOE B-NR: SGLT2 inhibitors (dapagliflozin 10mg daily, empagliflozin 10mg daily) should be considered in ACHD HF with reduced EF, particularly in patients with diabetes, obesity, or chronic kidney disease. Evidence emerging for benefit across HFrEF phenotypes beyond glycemic control.
Agent
Target Dose
Key Monitoring Parameters
ACHD-Specific Dose Adjustments
ACE-I (Lisinopril)
20-40 mg daily in divided doses
K+ (>5.5 concerning), Cr (watch for >30% increase), BP ≥90 systolic
Adjust for renal function; avoid if pregnancy planned; assess hyperkalemia risk especially in systemic RV patients
ARB (Losartan)
100-150 mg daily
K+, Cr, BP; same hyperkalemia monitoring as ACE-I
Alternative if ACE-I intolerance; similar efficacy; avoid pregnancy
ARNI (Sacubitril/Valsartan)
97/103 mg BID (starting 49/51 BID)
K+, Cr, BP (expect SBP 100-110); monitor for angioedema
Superior mortality benefit vs ACE-I/ARB in reduced EF; first-line consideration if available; contraindicated pregnancy; avoid with eGFR <30
Beneficial independent of diabetes; consider all HFrEF. Avoid if eGFR <20 or type 1 diabetes
Heart Transplantation in ACHD
Transplant Indications & Contraindications
COR 2a, LOE C-LD: Orthotopic heart transplantation should be considered in ACHD patients with end-stage HF refractory to optimal medical/device therapy (NYHA class III-IV despite maximum GDMT, repeated hospitalizations), severe refractory cyanosis unrelieved by medical management, uncontrolled malignant arrhythmias, or progressive hemodynamic/functional deterioration on optimal therapy despite maximal intervention.
COR 3, LOE C-LD: Transplantation not recommended in presence of: active systemic infection, uncorrectable pulmonary hypertension (transpulmonary gradient >15 mmHg, PVR >4-5 Wood units with reduced cardiac index), severe fixed elevated PVR without candidacy for mechanical circulatory support bridge, or inability to comply with lifelong immunosuppression.
Pre-Transplant Evaluation Components
Comprehensive Cardiac Assessment: Advanced imaging (cardiac MRI and/or CT) to define complex anatomy, assess ventricular function, quantify hemodynamics; echocardiography for valve function and thrombus
Systemic Organ Function Evaluation: Hepatic synthetic function testing (Fontan patients at high risk for cirrhosis; check INR, albumin, bilirubin, platelet count), renal function (eGFR, urine albumin), bone mineral density assessment (osteoporosis risk with CHD)
Psychosocial Evaluation: Psychiatric/psychology assessment for medication compliance history, substance use screening, support system adequacy, motivation for transplant, understanding of lifelong immunosuppression burden
Infectious Disease Screening: HIV, hepatitis B surface antigen and antibody, hepatitis C antibody, CMV serology, EBV serology, tuberculin skin test, relevant endemic mycoses (Coccidioides in Southwest U.S., Histoplasma in Mississippi Valley)
Transplant Referral Pitfall: Delaying transplant evaluation in progressive ACHD HF until NYHA class IV symptoms or acute decompensation substantially worsens outcomes. Early referral (ideally before NYHA IV or ICU admission) allows optimization pre-transplant, list activation with adequate time on waiting list, and significantly improves both short-term post-transplant survival and long-term graft survival. Transplant wait time often 1-3+ years; earlier listing optimizes survival probability.
Clinical Calculators & Evidence-Based Decision Support
Integrated clinical calculators assist with ACHD risk stratification, prognostication, and management optimization. Links below provide quick access to validated tools referenced throughout guideline management recommendations.
1. Lifelong Specialized Care Required: All ACHD patients require ongoing care at dedicated ACHD centers with multidisciplinary expertise. Outcomes demonstrably superior at specialized centers vs. general cardiology practices; regionalization of care strongly supported by evidence.
2. AP Classification System Foundation: The Anatomic and Physiologic classification system is essential for all ACHD management decisions. Determines surveillance intensity, testing frequency, intervention timing, and risk stratification. Remains the primary organizational framework for guideline recommendations.
3. Risk Stratification Essential for Outcomes: Use validated risk scores and multifactorial assessment (QRS duration, imaging parameters, arrhythmia burden) to identify high-risk patients for complications (sudden cardiac death, heart failure, arrhythmias). Early identification enables preventive interventions and improves long-term outcomes.
4. Reproductive Counseling Prevents Harm: Many ACHD lesions carry substantial maternal and fetal risk. Comprehensive preconception assessment, shared decision-making, and multidisciplinary planning for pregnancy significantly reduce maternal-fetal morbidity and mortality. Absolute contraindications exist for certain high-risk lesions; counseling essential.
5. Structured Transition Programs Prevent Loss to Follow-up: Adolescence-to-adulthood transition is highest-risk period for loss to follow-up in ACHD. Structured transition programs with dedicated coordinators, overlapping provider involvement, and regular assessment of transition readiness significantly improve long-term outcomes and prevent preventable complications.
6. Serial Surveillance Detects Progressive Changes: AP stage-based follow-up intervals with regular imaging (echocardiography, MRI/CT as indicated), biomarkers (BNP/NT-proBNP), and clinical assessment enable early detection of disease progression before symptomatic deterioration. Serial measurement superior to single-point assessment for management decisions.
7. Shared Decision-Making Optimizes Outcomes: Complex ACHD management requires collaborative discussions between patients, families, and multidisciplinary teams incorporating patient values, preferences, and life goals. Informed decision-making with transparent risk-benefit discussions improves adherence, satisfaction, and long-term outcomes.
8. Early Intervention Often Optimal: Earlier intervention at disease stage A-B often preferable to delayed intervention at stage C-D for many ACHD lesions. Examples: ASD closure with RV dilation on serial imaging, PVR before RVEF severely depressed, ToF arrhythmia management before SCD event. Prevention of deterioration superior to management of advanced disease.